Fresh Tracks Therapeutics Fresh Tracks Therapeutics Home
  • Company
    • Vision
    • Values
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partner With Us
    • Join Us
  • Scientific Innovations
  • Pipeline
    • Overview
    • FRTX-02
    • FRTX-10
    • Next-Generation Kinase Inhibitors
    • FRTX-03
  • Investor Relations
Main Menu
Contact Us
Investor Relations

News

Investors

Investors

  • Overview
  • News
  • Events
  • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
Sep 19, 2023 4:01pm EDT

Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution

Aug 11, 2023 4:01pm EDT

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 21, 2023 8:00am EDT

Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix

May 10, 2023 4:01pm EDT

Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Mar 30, 2023 4:01pm EDT

Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 07, 2023 4:01pm EST

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

Jan 27, 2023 8:00am EST

Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer

Jan 11, 2023 8:00am EST

Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity

Nov 10, 2022 4:05pm EST

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 03, 2022 4:05pm EDT

Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next Pagearrow_forward
  • Email Alerts
  • RSS News Feed

Company

  • Vision
  • Values
  • Leadership
  • Partner With Us
  • Join Us

Discover

  • Scientific Innovations
  • Pipeline
  • Investor Relations
  • News
  • Contact Us

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
  • Facebook
  • Compliance
  • Terms of Use
  • Privacy Policy
  • Accessibility
©2023 Fresh Tracks Therapeutics, Inc.

We use first- and third-party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this demonstrates your consent to receive all cookies or other tracking technologies on the FRTX website for the purposes described in our Privacy Policy. Please know that you can change your cookie settings at any time in your browser settings.

Close